"That’s something I’ve wondered for a long time - if we all know the potential of the drug, and their business is finding the next great drug, why has no one stepped up? The answer many state is that we haven’t gotten a ‘reasonable” offer. Why not? In this frothy environment for pharma, why has no one come after one of the indications aggressively?"
Read More: https://investorshangout.com/post/view?id=632...z7Hz0Yoa6M
"There are other drugs out there that will do one small part of what leronlimab will do. There is not another drug out there that covers so many indirect causes of illness in so many indications. That is because a disregulated immune system is responsible for so many of the causes and symptoms and CCR5 is a major controller of the immune system response."
Read More: https://investorshangout.com/post/view?id=6321980#Behavioral
To me, that is the major problem with the big pharmaceutical companies. Bringing Leronlimab into their pipeline, for any indication, would be disruptive to the rest of their pipeline. Once Leronlimab gets an approval, and becomes easily available, and the medical community becomes familiar with it, it's use has the potential to disrupt the entire concept of how drugs are developed and applied. It will force the medical community to look at immune system disregulation and inflammation as the underlying causes of many of our ailments.
In a perfect world, Leronlimab would be stocked in every emergency room, and pharmacy, in the world. It would/should be the first thing the doctor reaches for in many instances of medical need.
Would you bring in the one thing that could destroy the status quo, if your company was making billions by making the status quo? The status quo being, to make a little poison to treat a little bit of what ails you. Then, make a little more poison to treat the previous poisons.